315 related articles for article (PubMed ID: 16286244)
1. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Neviani P; Santhanam R; Trotta R; Notari M; Blaser BW; Liu S; Mao H; Chang JS; Galietta A; Uttam A; Roy DC; Valtieri M; Bruner-Klisovic R; Caligiuri MA; Bloomfield CD; Marcucci G; Perrotti D
Cancer Cell; 2005 Nov; 8(5):355-68. PubMed ID: 16286244
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Ferrari-Amorotti G; Keeshan K; Zattoni M; Guerzoni C; Iotti G; Cattelani S; Donato NJ; Calabretta B
Blood; 2006 Aug; 108(4):1353-62. PubMed ID: 16670262
[TBL] [Abstract][Full Text] [Related]
3. Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Chai JH; Zhang Y; Tan WH; Chng WJ; Li B; Wang X
BMC Cancer; 2011 Dec; 11():512. PubMed ID: 22151181
[TBL] [Abstract][Full Text] [Related]
4. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
Chang JS; Santhanam R; Trotta R; Neviani P; Eiring AM; Briercheck E; Ronchetti M; Roy DC; Calabretta B; Caligiuri MA; Perrotti D
Blood; 2007 Aug; 110(3):994-1003. PubMed ID: 17475908
[TBL] [Abstract][Full Text] [Related]
5. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
[TBL] [Abstract][Full Text] [Related]
6. IRF-4 functions as a tumor suppressor in early B-cell development.
Acquaviva J; Chen X; Ren R
Blood; 2008 Nov; 112(9):3798-806. PubMed ID: 18713947
[TBL] [Abstract][Full Text] [Related]
7. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model.
Nagamachi A; Yamasaki N; Miyazaki K; Oda H; Miyazaki M; Honda Z; Kominami R; Inaba T; Honda H
Cancer Sci; 2009 Jul; 100(7):1219-26. PubMed ID: 19432895
[TBL] [Abstract][Full Text] [Related]
8. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells.
Guerzoni C; Bardini M; Mariani SA; Ferrari-Amorotti G; Neviani P; Panno ML; Zhang Y; Martinez R; Perrotti D; Calabretta B
Blood; 2006 May; 107(10):4080-9. PubMed ID: 16418324
[TBL] [Abstract][Full Text] [Related]
9. Acquired miR-142 deficit in leukemic stem cells suffices to drive chronic myeloid leukemia into blast crisis.
Zhang B; Zhao D; Chen F; Frankhouser D; Wang H; Pathak KV; Dong L; Torres A; Garcia-Mansfield K; Zhang Y; Hoang DH; Chen MH; Tao S; Cho H; Liang Y; Perrotti D; Branciamore S; Rockne R; Wu X; Ghoda L; Li L; Jin J; Chen J; Yu J; Caligiuri MA; Kuo YH; Boldin M; Su R; Swiderski P; Kortylewski M; Pirrotte P; Nguyen LXT; Marcucci G
Nat Commun; 2023 Sep; 14(1):5325. PubMed ID: 37658085
[TBL] [Abstract][Full Text] [Related]
10. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 2A: a target for anticancer therapy.
Perrotti D; Neviani P
Lancet Oncol; 2013 May; 14(6):e229-38. PubMed ID: 23639323
[TBL] [Abstract][Full Text] [Related]
12. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
Perrotti D; Neviani P
Cancer Metastasis Rev; 2008 Jun; 27(2):159-68. PubMed ID: 18213449
[TBL] [Abstract][Full Text] [Related]
13. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
14. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.
Seshacharyulu P; Pandey P; Datta K; Batra SK
Cancer Lett; 2013 Jul; 335(1):9-18. PubMed ID: 23454242
[TBL] [Abstract][Full Text] [Related]
15. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
[TBL] [Abstract][Full Text] [Related]
17. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
18. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.
Perrotti D; Neviani P
Br J Cancer; 2006 Oct; 95(7):775-81. PubMed ID: 16953242
[TBL] [Abstract][Full Text] [Related]
19. Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease.
Yu G; Yan T; Feng Y; Liu X; Xia Y; Luo H; Wang JZ; Wang X
Neurobiol Aging; 2013 Jul; 34(7):1748-58. PubMed ID: 23374587
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Oaks JJ; Santhanam R; Walker CJ; Roof S; Harb JG; Ferenchak G; Eisfeld AK; Van Brocklyn JR; Briesewitz R; Saddoughi SA; Nagata K; Bittman R; Caligiuri MA; Abdel-Wahab O; Levine R; Arlinghaus RB; Quintas-Cardama A; Goldman JM; Apperley J; Reid A; Milojkovic D; Ziolo MT; Marcucci G; Ogretmen B; Neviani P; Perrotti D
Blood; 2013 Sep; 122(11):1923-34. PubMed ID: 23926298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
